Biotech Insider is the most expensive product in Dylan Jovine’s Behind the Markets lineup. The flagship Behind the Markets service costs $49 per year, and Biotech Insider starts at $2,997 — a price gap that tells you who the product is for. This is a specialized research service built for investors who want clinical-stage biotech exposure and are willing to pay for the analysis that goes into evaluating late-phase drug trials.
The service targets small and mid-cap biotech companies in late Phase II and Phase III clinical trials. The thesis is specific: companies near the end of the clinical trial cycle have the highest probability of a binary catalyst, either FDA approval or a partnership with a major pharmaceutical company. Jovine described his own approach on his personal blog at dylanjovine.com on July 16, 2020: “The stocks we recommend at Biotech Insider are in either the start-up phase or the growth phase of their life cycle. By nature that means these investments are high-risk, high-return investments. Sometimes comically volatile.”
He was direct about the downside. “Here at Biotech Insider we expect 30% of the investments we make to lose money.”
That is the most honest sentence in financial newsletter marketing. Most services bury the risk in disclaimers. Jovine put it in his own voice, on his own blog, in plain English. The venture capital comparison he drew is accurate. Biotech investing at this stage is binary: a Phase III trial succeeds and the stock doubles, or it fails and the stock drops 70%. The math works if the winners are big enough to cover the losers, and Jovine built the service around that assumption.
What Biotech Insider Is
Biotech Insider is a monthly research service publishing one biotech stock recommendation per month. The focus is companies with market capitalizations too small for institutional research coverage. The pitch is that individual investors have an edge here because mutual funds and hedge funds cannot build meaningful positions in micro-cap biotechs without moving the price.
Subscribers get the monthly research report, real-time trade alerts when clinical trial data or regulatory decisions hit, access to the model portfolio with all open and closed positions, and a set of educational resources. Six bonus reports ship with new subscriptions, covering portfolio construction, income generation from biotech holdings, and framework guides for evaluating clinical-stage companies.
The service lists three pricing tiers: the annual plan at $2,997 for 12 months, the two-year plan at $3,997, and the VIP Unlimited plan at $4,997 lasting as long as the service publishes. All three come with the same core features and a 30-day money-back guarantee.
The Known Picks
Biotech Insider does not publish a dedicated track record page like the flagship Behind the Markets service, which posts 70 closed trades with a 72.9% win rate and 39.96% CAGR on a dedicated page. Past performance does not guarantee future results. The observable record for Biotech Insider comes from third-party tracking and subscriber reports.
Recursion Pharmaceuticals (RXRX) was pitched in March 2025 as the “End of Disease” pick, highlighted for its AI drug discovery platform, NVIDIA’s investment of 7 million shares, and a Bayer partnership worth up to $1.5 billion. The stock was around $7 at the time of the pitch. By mid-2025, RXRX had dropped to approximately $2.62, a decline of roughly 40%. Recursion remains pre-revenue with no drugs past Phase 2 clinical trials.
Viking Therapeutics (VKTX) was recommended at approximately $14 in August 2023. The stock rose to around $19, a gain of roughly 33%. Viking’s GLP-1 franchise gave the position fundamental momentum. Eli Lilly (LLY) was recommended as a obesity drug play and gained approximately 27% from the recommendation point. Novo Nordisk (NVO) gained roughly 30% over five months following its recommendation.
Editas Medicine (EDIT) was recommended in late 2018 as a CRISPR gene-editing play. The stock experienced a brief spike of approximately 400% in early 2021 during the biotech mania, then declined roughly 90% from that peak. Denali Therapeutics (DNLI) was recommended in September 2021 for its Alzheimer’s drug pipeline. The stock declined approximately 50% from the recommendation point.
These picks span the full distribution Jovine described, with Viking, Eli Lilly, and Novo Nordisk running with the thesis and Recursion, Editas, and Denali running against it. The spread between outcomes is wide enough that position sizing shapes the portfolio result as much as pick selection. A subscriber who put equal money in all six would have seen both sides of the binary. The distribution is exactly what a 30% expected loss rate produces — roughly a third of the picks declined, and the winners carried enough weight to keep the portfolio in play. Past performance does not guarantee future results.
How the Strategy Works
Jovine’s biotech methodology has two components. The first is clinical trial staging. He focuses on companies in late Phase II or Phase III trials because that is where regulatory catalysts cluster. A successful Phase III readout can move a stock 50% in a day, and an FDA advisory committee vote can move it more, so the strategy is to be positioned before those events.
The second component is partnership and acquisition potential. Large pharmaceutical companies face patent cliffs and need new drugs in their pipelines. Buying a smaller company with a promising late-stage asset is faster and cheaper than developing one internally. Jovine’s background in identifying takeover targets, the skill that built his career in the 1990s, translates directly to biotech M&A.
The combination creates two paths to returns: a clinical trial succeeds and the stock appreciates on fundamentals, or a larger company acquires the biotech at a premium. Both have happened in the observable track record. The 30% expected loss rate means a third of positions will fail on one or both paths — the structure of the service accounts for this by design.
What You Are Paying For
The $2,997 annual price puts Biotech Insider in the premium tier of investment newsletters. For context, entry-level newsletters in this space typically run $49 to $89 per year for a first-year subscription.
Biotech Insider costs 60 times the entry-level newsletter. The premium reflects specialization. Biotech research requires reading clinical trial data, understanding FDA regulatory pathways, and tracking the competitive landscape for specific drug candidates. The monthly report does that work for subscribers who do not have the expertise or time to evaluate Phase III trial endpoints on their own.
The 30-day refund window is shorter than the typical clinical trial catalyst cycle. A subscriber who joins in month one can evaluate the research quality, the model portfolio, and the educational materials within the refund window. Biotech catalysts run on FDA timelines, which move in months and quarters, not days. The 30-day window is built for evaluating the research, not for catching a catalyst.
What Makes Biotech Insider Stand Out
Biotech Insider concentrates in a single sector with binary outcomes. The 30% expected loss rate is Jovine’s own number, and the known picks show both sides of that distribution: Viking and Eli Lilly up, Recursion and Denali down. The service is built around that distribution, and the price reflects the research intensity. Reading Phase III data and regulatory filings is specialized work. An investor allocating $50,000 to biotech positions is paying 6% of capital for the research. An investor allocating $5,000 is paying 60%. The economics scale with portfolio size, and the premium over entry-level newsletters buys clinical trial analysis that $89 services do not produce.
The 30-day refund gives a window to read the current research, check the model portfolio against what is publicly known, and evaluate Jovine’s approach to biotech. The honesty about expected losses is the defining characteristic of the service. A research product that tells you 30% of picks will fail is one that sets real expectations about clinical-stage investing, and that transparency extends through the rest of the research. The Breakthrough Wealth review covers the micro-cap moonshot tier of the same publisher’s lineup. More newsletter and service reviews are collected at the Newsletter Reviews hub.